{"id":"aspegic-aspirin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":"1-2","effect":"Hemorrhage (minor)"},{"rate":"0.5-2.5","effect":"Hypersensitivity reactions (in aspirin-sensitive patients)"}]},"_chembl":{"chemblId":"CHEMBL25","moleculeType":"Small molecule","molecularWeight":"180.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of prostaglandins (which mediate inflammation and pain) and thromboxane A2 (which promotes platelet clumping). The antiplatelet effect is particularly important at low doses, where COX-1 inhibition in platelets predominates, making aspirin useful for cardiovascular protection.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:44.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction prevention and secondary prevention"},{"name":"Ischemic stroke prevention"},{"name":"Transient ischemic attack (TIA) prevention"},{"name":"Mild to moderate pain and fever"},{"name":"Rheumatoid arthritis and other inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT00986765","phase":"PHASE3","title":"Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-06","conditions":"Preeclampsia","enrollment":257},{"nctId":"NCT00910065","phase":"PHASE3","title":"BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":"Acute Coronary Syndrome","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":106,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aspegic ® (Aspirin)","genericName":"Aspegic ® (Aspirin)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation. Used for Acute myocardial infarction prevention and secondary prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}